| Tissue-dependent tumor microenvironments and their impact on immunotherapy responses AJ Oliver, PKH Lau, AS Unsworth, S Loi, PK Darcy, MH Kershaw, ... Frontiers in immunology 9, 325650, 2018 | 152 | 2018 |
| Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma J Aleksova, PKH Lau, G Soldatos, G McArthur Case Reports 2016, bcr2016217454, 2016 | 100 | 2016 |
| Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma S AbuHammad, C Cullinane, C Martin, Z Bacolas, T Ward, H Chen, ... Proceedings of the National Academy of Sciences 116 (36), 17990-18000, 2019 | 88 | 2019 |
| Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A … EL Mitchell, PKH Lau, C Khoo, D Liew, J Leung, B Liu, A Rischin, ... European Journal of Cancer 105, 88-102, 2018 | 59 | 2018 |
| Activation of canonical BMP4-SMAD7 signaling suppresses breast cancer metastasis BL Eckhardt, Y Cao, AD Redfern, LH Chi, AD Burrows, S Roslan, ... Cancer research 80 (6), 1304-1315, 2020 | 48 | 2020 |
| FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment A Iravani, MM Osman, AM Weppler, R Wallace, A Galligan, A Lasocki, ... European journal of nuclear medicine and molecular imaging 47, 2776-2786, 2020 | 46 | 2020 |
| Factors associated with psychological distress amongst outpatient chemotherapy patients: An analysis of depression, anxiety and stress using the DASS-21 M McMullen, PKH Lau, S Taylor, J McTigue, A Cook, M Bamblett, ... Applied Nursing Research 40, 45-50, 2018 | 45 | 2018 |
| Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection P Kar Han Lau, ML Woods, S Kanneyalal Ratanjee, G Tharayil John Clinical Infectious Diseases 52 (2), 279-279, 2011 | 44 | 2011 |
| A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies CW Guo, M Alexander, Y Dib, PKH Lau, AM Weppler, G Au-Yeung, B Lee, ... European journal of cancer 124, 15-24, 2020 | 39 | 2020 |
| Bevacizumab as a steroid‐sparing agent during immunotherapy for melanoma brain metastases: A case series PD Banks, A Lasocki, PKH Lau, S Sandhu, G McArthur, M Shackleton Health Science Reports 2 (3), e115, 2019 | 35 | 2019 |
| Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death‐1 monoclonal antibodies for advanced melanoma A Wong, M Williams, D Milne, K Morris, P Lau, O Spruyt, S Fullerton, ... Asia‐Pacific Journal of Clinical Oncology 13 (6), 385-390, 2017 | 31 | 2017 |
| A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy EJ Lelliott, C Cullinane, CA Martin, R Walker, KM Ramsbottom, ... Scientific reports 9 (1), 1225, 2019 | 30 | 2019 |
| The evaluation of a clinical scar scale for porcine burn scars XQ Wang, O Kravchuk, PY Liu, M Kempf, CVD Boogaard, P Lau, L Cuttle, ... Burns 35 (4), 538-546, 2009 | 30 | 2009 |
| Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition PKH Lau, PA Ascierto, G McArthur Current Opinion in Immunology 39, 30-38, 2016 | 27 | 2016 |
| Patients prefer chemotherapy on the same day as their medical oncology outpatient appointment PKH Lau, MJ Watson, A Hasani Journal of oncology practice 10 (6), e380-e384, 2014 | 22 | 2014 |
| Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) PKH Lau, B Feran, L Smith, A Lasocki, R Molania, K Smith, A Weppler, ... Journal for Immunotherapy of Cancer 9 (10), 2021 | 20 | 2021 |
| A pilot study to assess the validity of the DASS-21 subscales in an outpatient oncology population. CE Johnson, KS Bennett, J Newton, J McTigue, S Taylor, T Musiello, ... Psycho-oncology 27 (2), 2018 | 16 | 2018 |
| Combined BRAF, MEK, and CDK4/6 inhibition depletes intratumoral immune-potentiating myeloid populations in melanoma EJ Lelliott, S Mangiola, KM Ramsbottom, M Zethoven, L Lim, PKH Lau, ... Cancer Immunology Research 9 (2), 136-146, 2021 | 13 | 2021 |
| Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases ML Hilbers, F Dimitriou, P Lau, P Bhave, GA McArthur, L Zimmer, ... European Journal of Cancer 156, 149-163, 2021 | 11 | 2021 |
| High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges A Lasocki, C Khoo, PKH Lau, DL Kok, GA McArthur Neuro-oncology 22 (3), 423-432, 2020 | 11 | 2020 |
Grant McArthurPeter MacCallum Cancer CentreVerified email at petermac.org
